# Ticagrelor

## Brilinta 90mg

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                             |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | OBRI                                                                                                                                                                                                                                                                                                             |
| 適應症     | Prevention of atherothrombotic events in patients w/ acute coronary syndromes (ACS) [unstable angina, non-ST elevation MI (NSTEMI) or ST elevation MI (STEMI)] including patients managed medically & managed w/ percutaneous coronary intervention (PCI) or CABG co-administered w/ acetylsalicylic acid (ASA). |
| 用法用量   | Acute coronary heart disease: loading dose as 180mg and followed by 90mg BID for 12 months. Patient with MI history combined with high risk of arterial thrombosis, needed an extended treatment: 60mg BID.                                                                                                      |
| 肝功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                       |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                     |
| 禁忌       | Active pathological bleeding, history of intracranial haemorrhage, moderate to severe hepatic impairment, co-administration w/ strong CYP3A4 inhibitors.                                                                                                                                                         |
| 副作用     | Dyspnoea, epistaxis, GI haemorrhage, subcutaneous or dermal bleeding, bruising, procedural site haemorrhage.                                                                                                                                                                                                     |
| 孕期建議   | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                               |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                             |

